AGC Inc. (TYO:5201) is looking to invest more than 200 billion yen ($1.7 billion) into CDMO operations by 2025. Plans…...
Please subscribe to read the full story.
cell therapy
Nissan Chemical Enables Mass Cell Culture With New Substrate
Nissan Chemical Corp. (TYO:4021) has developed FCeM Cellhesion, a cell culture substrate allowing for the mass culture of mesenchymal stem…...
Please subscribe to read the full story.
Daiichi Sankyo Partners With US Firm to Enter Cancer Cell Therapy Market
Daiichi Sankyo Co. Ltd. (TYO:4568) is entering Japan’s market for anti-cancer cell therapy drugs in partnership with U.S.-based Kite Pharma…...
Please subscribe to read the full story.
